Roche Reports the US FDA’s Acceptance of NDA for Risdiplam and Granted Priority Review to Treat Spinal Muscular Atrophy

Shots:

• The NDA submission is based on FIREFISH Part-1 and SUNFISH Part-2 studies. The FIREFISH (Part 1 & 2) study involves assessing Risdiplam in 21 & 41 infants aged 1-7mos. with SMA, followed by an open-label extension respectively
• The SUNFISH (Part 1 & 2) study involves assessing Risdiplam vs PBO in children & young adults aged 2-25yrs. with Type 2 or 3 SMA. Part 2 study resulted in meeting its 1EPs i.e, change in the Motor Function Measure 32 (MFM-32) scale, the safety profile is consistent with no new safety signals
• Risdiplam (PO) is an investigational SMN-2 splicing modifier, designed to increase and sustain SMN protein levels both via CNS and peripheral tissues of the body and has received FDA’s ODD and FT designation In Jan’17 & Apr’17 respectively with its expected PDUFA date as May 24, 2020

Click here to­ read full press release/ article | Ref: Roche | Image: Roche